Investing.com -- Goldman Sachs has shifted its ratings stance on European chemicals, moving to a more pro-cyclical view and announcing seven rating changes across the sector, citing early signs of ...

TJC LP (“TJC” or “the Firm”), a middle-market private equity firm investing primarily in North America, today announced that the Firm earned the #4 ranking on the HEC Paris-Dow Jones 2025 Global ...

Francisco Partners Ranks in Top Three of the HEC Paris-Dow Jones Annual Global Large Buyout Performance Ranking for Sixth Consecutive Year #2 ranking reflects consistent strong performance over the ...

Tyson Foods Inc. reported a significant drop in its first-quarter earnings as the company deals with losses in its beef segment. The Springdale-based company posted a net income of $85 million, or an ...

Coca-Cola is reiterated as a strong sell due to overvaluation and stagnating core product volume growth. KO's recent earnings beat was driven by unsustainable forex tailwinds and aggressive pricing, ...

Silver is now a front-page asset on Hyperliquid, highlighting a subtle shift in how crypto derivatives venues are being used as bitcoin struggles to find direction. The SILVER-USDC contract has become ...

The MarketWatch News Department was not involved in the creation of this content. PANAMA CITY, Dec. 05, 2025 (GLOBE NEWSWIRE) -- As on-chain derivatives continue to expand at record pace, the ...

Caterpillar Inc. CAT reported a turnaround in volume performance in the second quarter of 2025, with a net volume increase of $237 million. This marks a significant recovery after six straight ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

The J. M. Smucker Company SJM enters fiscal 2026 under pressure, grappling with gross margin headwinds due to persistent cost inflation, unfavorable product mix and soft volumes. In fourth-quarter ...

Revolution Medicines has secured a potential funding infusion of up to $2 billion from Royalty Pharma in return for a slice of the profits if Revolution’s lead cancer drug makes it to market.